About vaccines

Authors from varying Canadian institutes report on two-dose vaccine effectiveness against infection and hospitalization. // 28.10.2021

Researchers emphasize that an effective vaccine should induce mucosal immunity and prevent the nasal entry of SARS-CoV-2. // 27.10.2021

A new study, published on the medRxiv* preprint server, has focused on the use of anti-nucleocapsid (N) antibody positivity as a marker of SARS-CoV-2 infection. In the present study, these antibody markers were evaluated using serological surveillance studies post-vaccination amidst circulation of variants of concern. // 28.10.2021

In a study published in Annals of Internal Medicine, researchers from Italy systematically monitored 2,397 HCWs who were fully vaccinated with BNT162 at the ASST Settelaghi hospitals in Lombardy, Italy during February 2021. HCWs who worked in 8 wards deemed at “high risk” for infection from attending patients had to undergo mandatory nasopharyngeal swab testing with SARS-CoV-2 polymerase chain reaction every two weeks. HCWs working in 8 “moderate-risk” wards were tested every four weeks. // 28.10.2021

Researchers in the United States have conducted a large-scale study showing that the two-dose regimen vaccines developed by Pfizer-BioNTech and Moderna to protect against coronavirus disease 2019 (COVID-19) appear to be highly effective and durable in reducing the risk of hospitalizations and deaths following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). // 28.10.2021

Researchers at the University of Oxford have conducted a study showing that vaccination against coronavirus disease 2019 (COVID-19) is associated with a lower risk of several sequelae among those who experience breakthrough infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). // 28.10.2021

The heterologous ChAd/BNT combination confers better protection against SARS-CoV-2 infection than the homologous BNT/BNT combination in a real-world observational study of healthcare workers. // 27.10.2021

Researchers collaborated to address these evidence gaps by initiating a web-based prospective study of adults diagnosed with multiple myeloma to determine the immune response to the first and second dose of the COVID-19 vaccine. // 27.10.2021

Researchers in the United States have conducted a study showing that Moderna’s coronavirus disease 2019 (COVID-19) vaccine provided durable protection against the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in rhesus macaques. // 26.10.2021

A recent study by researchers from the Netherlands highlights that the introduction of vaccination programs against coronavirus disease 2019 (COVID-19) to adolescents and children may reduce infection rates and severe disease outcomes – both in these age groups and in the population as a whole. // 26.10.2021

Study looks at outcomes for 32 million people in England // 26.10.2021

Researchers from the University of Oxford have recently analyzed pregnancies that have occurred during four ChAdOx1 nCoV-19 clinical trials. // 26.10.2021

Israeli researchers evaluate the antibody response in ICPs to assess antibody-mediated immunity following vaccination with the Pfizer-BioNTech vaccine. //26.10.2021

A paper claiming that cases of myocarditis spiked after teenagers began receiving COVID-19 vaccines that earned a “temporary removal” earlier this month will be permanently removed, according to a publisher at Elsevier.

https://www.biorxiv.org/content/10.1101/2021.10.23.465542v1 // 24.10.2021

A new study posted to the medRxiv* preprint server studies the neutralizing antibody response in cancer patients diagnosed with chronic lymphocytic leukemia (CLL), lung cancer, breast cancer, and various non-Hodgkin’s lymphomas (NHL), post-reception of two doses of messenger RNA (mRNA) vaccines. // 24.10.2021

Background A cluster of over a thousand infections with the SARS-CoV-2 delta variant was identified in a predominantly fully vaccinated population in Provincetown, Massachusetts in July 2021. Immune responses in breakthrough infections with the SARS-CoV-2 delta variant remain to be defined. // 20.10.2021

Researchers compare antibody titers elicited the Pfizer‐BioNTech mRNA and the classic inactivated virus Sinopharm vaccines. // 24.10.2021

Researchers report the binding and pseudo-neutralizing antibody titers elicited after patients had received either the Pfizer-BioNTech or AstraZeneca vaccines. // 24.10.2021

In a recent study, researchers from the U.S. examined the vaccine effectiveness against SARS-CoV-2 infections in Puerto Rico. // 24.10.2021

This report describes lower non-COVID-19 death rates among COVID-19 vaccinated people.

Nature - Companies are updating vaccines and testing them on people to prepare for whatever comes next in the pandemic. // 20.10.2021

Original Article from The New England Journal of Medicine — Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months // 15.9.2021 Through 6 months of follow-up and despite a gradual decline in vaccine efficacy, BNT162b2 had a favorable safety profile and was highly efficacious in preventing Covid-19

Only a third of seronegative patients had T-cell responses after vaccination // 21.10.2021

Vaccination is over 90 per cent effective at preventing deaths from the Delta variant of Covid-19, according to the first country-level data on mortality. // 21.10.2021

In a recent study, researchers compared the efficacy of the Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines against infection SARS-CoV-2. //21.10.2021

A recent study from the United Kingdom, published in the open-access journal Vaccines, implies that vaccinating adolescents and children may be pivotal in reducing infections with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as well as ensuing coronavirus disease (COVID-19) morbidity and mortality across all age groups. // 21.10.2021

You might have fewer antibodies now. But they’re better than the ones you started with. // 21.10.2021

A clinical study by a team of scientists from Norway aimed to assess the immunogenicity and safety of a third dose of COVID-19 mRNA vaccine in MS patients treated with anti-CD20 therapy or fingolimod. / 20.10.2021

A study of breakthrough infections in immunocompromised people following two doses of the Pfizer/BioNTech vaccine against SARS-CoV-2 concluded that immunocompromised people would be best served with a third dose of the vaccine for better protection. // 19.10.2021